SAN MATEO, Calif. (AP) ¿ NeurogesX Inc. said Wednesday it will study Qutenza as a treatment for nerve pain caused by shingles or diabetes, following an agreement with the Food and Drug Administration.

The drug will be tested as a potential treatment for post-herpetic neuralgia following pretreatment with an FDA-approved topical anesthetic.

The FDA is currently reviewing Qutenza as a potential treatment for the nerve pain condition, with a decision expected by Aug. 16.

The new study will involve 20 patients receiving the pain patch after a 60-minute pretreatment with an FDA-approved topical anesthetic. The goal of the study is the mean duration of the patch application.

Qutenza is already approved in Europe.

The drug had a slight setback in 2008, when it failed to reduce nerve pain in a late-stage study of HIV patients. At the time, though, it produced positive results in post-herpetic neuralgia.

Lazard Capital Markets analyst William Tanner reaffirmed a "Buy" rating and $8 target price on the stock, citing the study agreement with the FDA.

"Following European Union approval of Qutenza, we believe commercial prospects for the company are improving," he said, in a note to investors.

The company could announce a European partnership soon, he said.

Shares rose 14 cents, or 2.4 percent, to $6.09 in midday trading. The stock reached a new 52-week high of $6.25 earlier in the trading session.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

If you liked this article you might like

What's Behind the Surge in Energy Stocks

What's Behind the Surge in Energy Stocks

Hillary Clinton Says Prosecuting Individuals is Key to Wall Street Reform

Hillary Clinton Says Prosecuting Individuals is Key to Wall Street Reform